Voglibose 0.2 Mg + Glimepiride 1 Mg + Metformin Hydrochloride 500 Mg Sr

The combination is indicated for the treatment of type 2 diabetes when diet and exercise alone do not provide adequate glycemic control.

The dosage may vary, and it should be determined by a healthcare professional based on the patient's individual needs and response to treatment.

Common side effects may include gastrointestinal symptoms such as nausea, diarrhea, and abdominal discomfort. Hypoglycemia (low blood sugar) is a potential side effect, particularly with Glimepiride.

It's important to monitor for signs of hypoglycemia and adjust the dosage accordingly. The combination is contraindicated in patients with hypersensitivity to any of its components.

https://www.centaurpharma.com/downloads/Glimitab-MV2018.pdf Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi:10.2337/dc14-2441.

The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Voglibose (Alpha-glucosidase inhibitors) are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates specifically alpha-glucosidase enzymes in the brush border of the small intestines.

DIABETIC